News

Akari & USAISR team up for potential trauma therapy

Akari Therapeutics enters agreement with US Army Institute of Surgical Research for nomacopan
Written byMel J. Yeates
| 2 min read

NEW YORK & LONDON—Akari Therapeutics has announced that the company has entered a cooperative research and development agreement with the US Army Institute of Surgical Research (USAISR). The collaboration will evaluate the potential for use of Akari’s nomacopan in civilian and battlefield trauma injuries for which there are currently no approved therapies, using preclinical trauma and hemorrhages shock models.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.